Cardiac Rhythm Management Devices Market, By Product (Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices), By Application (Congestive heart failure, Arrhythmias, Bradycardia, Tachycardia, and Others), By End users (Hospitals, Cardiac care centers, Ambulatory surgical centers, Other), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)
In May 2024, Royal Philips presented a new research at the Heart Rhythm Annual Meeting in Boston, U.S., showcasing the benefits of its AI-powered cardiac care solutions. The studies emphasize how mobile cardiac monitoring, like Philips' MCOT wearable ECG sensor, improves early detection of cardiac events, reduces readmissions, and cuts costs compared to implantable loop recorders (ILRs).
In October 2023, MicroPort CRM announced the launch of the ULYS Implantable Cardioverter Defibrillator (ICD) and the INVICTA defibrillation lead in Japan. This move aims to enhance their global product portfolio.
In October 2023, Boston Scientific introduced its latest innovation, the LUX-Dx II+ insertable cardiac monitor (ICM) system. This advanced system offers extended monitoring capabilities for arrhythmias associated with conditions like atrial fibrillation (AFib), cryptogenic stroke, and syncope.
In April 2022, Abbott revealed that the U.S. FDA had approved its Aveir single-chamber (VR) leadless pacemaker. This approval, designed to treat patients with slow heart rhythms in the U.S., marks a significant advancement in patient care by offering new, innovative features for both patients and healthcare providers.